Ligand Pharmaceuticals will pay $23 million upfront for 100% of certain Royalty and milestone rights tied to Santen’s Ryjunea in Europe, the Middle East and Africa. The deal matters to investors because Ligand will receive tiered low-double-digit to high-teens royalties on Ryjunea net sales in those territories, plus certain milestone payments.
Key Highlights
- Ryjunea has European Commission and UK MHRA approval as a pharmacological treatment intended to slow myopia progression in pediatric patients.
- Ryjunea uses a standardized 0.01% atropine formulation with deuterated water.
- Sydnexis retains Ryjunea commercial rights in the United States and territories outside those licensed to Santen.
$23 Million Purchase Covers Ryjunea Payment Rights
LIGAND PHARMACEUTICALS INC (NASDAQ: LGND) is a Pharmaceuticals: Major company. Certain milestone payments are included as well. Sydnexis keeps Ryjunea commercial rights in the United States and in territories outside those licensed to Santen. Santen obtained its EMEA rights from Sydnexis in 2021, while Ligand’s acquired interest covers payments under that arrangement. The product uses a standardized 0.01% atropine formulation with deuterated water, which the release says was designed to improve efficacy, comfort and stability for pediatric use. Ligand also expects certain reimbursement approval and sales milestones connected with Ryjunea.
FAQs
Q: How much is Ligand Pharmaceuticals paying for Ryjunea royalty rights?
A: Ligand Pharmaceuticals is paying $23 million upfront for a 100% interest in certain Ryjunea royalty, milestone and related payment rights under Sydnexis’s agreement with Santen.
Q: What formulation does Ryjunea use?
A: Ryjunea uses a standardized 0.01% atropine formulation with deuterated water. The product is a once-nightly, low-dose eye drop designed for pediatric myopia progression.
Q: When did Santen license Ryjunea rights from Sydnexis?
A: Santen licensed Ryjunea rights from Sydnexis in 2021.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.